Transfected 293T Cells Research Articles

Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Assocciated Domain (TEAD) PROTAC Degraders.

Dysregulation of the Hippo pathway has been observed in various cancers. The transcription factor TEAD, together with its coactivators YAP/TAZ, plays a crucial role in regulating the transcriptional output of the Hippo pathway. Recently, extensive research has focused on small molecule inhibitors targeting TEAD, but studies on TEAD degraders are comparatively rare. In this study, we designed and synthesized a series of TEAD PROTACs by connecting a pan-TEAD inhibitor with the CRBN ligand thalidomide. A representative compound, 27, exhibited potent antiproliferative activity against NF2-deficient NCI-H226 cells. It dose-dependently induced TEAD degradation dependent on CRBN and proteasome system and decreased key YAP target genes CYR61 and CTGF expressions in NCI-H226 cells. Further degradation selectivity studies revealed that 27 exhibited more potent activity against TEAD2 compared to those of the other three family members in Flag-TEADs transfected 293T cells. Therefore, 27 may serve as a valuable tool for advancing biological studies related to TEAD2.

Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy.

Islatravir is a new antiretroviral drug that inhibits the reverse transcriptase (RT) of HIV-1 through multiple mechanisms. It is proposed to be used in combination with doravirine, a new NNRTI. M184V/I mutations have been shown to reduce the in vitro antiviral activity of islatravir, but their effect when pre-selected during ART has not been investigated. HIV-1 rt sequences were obtained from four individuals of the Garrahan HIV cohort prior to, or during virological failure to ART. HIV-1 infectious molecular clones were constructed on an NL4-3 backbone, and infectious viruses were produced by transfection of 293T cells. Fold-changes in IC50 were calculated for each mutant versus the NL4-3 WT. HIV-1 phenotypic drug resistance was tested in vitro against NRTIs and NNRTIs. In all the cases, M184I/V, either alone or in the presence of other mutations, was associated with reduced susceptibility to islatravir, abacavir and lamivudine. Viruses carrying M184V/I showed variable levels of resistance to islatravir (4.8 to 33.8-fold). The greatest reduction in susceptibility was observed for viruses carrying the mutations M184V + V106I (33.8-fold resistance) or M184V + I142V (25.2-fold resistance). For NNRTIs, the presence of V106I alone did not affect susceptibility to doravirine or etravirine, but showed a modest reduction in susceptibility to efavirenz (6-fold). Susceptibility to doravirine was slightly reduced only for one of the mutants carrying V106I in combination with Y181C and M184V. Mutations and polymorphisms selected in vivo together with M184V/I depend on the viral genetic context and on ART history, and could affect the efficacy of islatravir once available for use in the clinic.

Non-Activating Integrin β3(R734C) Mutation Associated with Macrothrombocytopenia and Impaired Platelet Function

Introduction We and others identified several mutations in ITGA2B or ITGB3 associated with congenital macrothrombocytopenia. These mutations are located around transmembrane domains of αIIb or β3, and basically induce constitutive activation of αIIbβ3. Recently, we identified a mutation, β3(R734C), which is located in cytoplasmic tail of β3 without inducing αIIbβ3 activation in a Japanese family with macrothrombocytopenia. We analyzed the effect of the mutation on platelet production and function using knock-in (KI) mice. Cases and Transfection assay The proband was a 14-year-old Japanese girl, who showed macrothrombocytopenia with 60-90 x 10 9/L platelet counts and mild bleeding tendency. Her mother, her maternal aunt and a cousin also showed macrothrombocytopenia. The expression of αIIbβ3 on their platelets was decreased to ~50% of healthy control. GPVI expression was decreased, whereas GPIb expression was increased probably due to the increase in platelet size. Genetic analysis revealed that all affected subjects were heterozygous of β3(R734C) mutation. No PAC-1 binding was observed to the platelets of the affected subjects or αIIbβ3(R734C)-transfected 293T cells, indicating that the mutation does not cause αIIbβ3 activation. Methods and Results of mouse studies We generated β3(R734C) KI mouse (C57BL6/J background) by CRISPR/Cas9-mediated genome editing. The β3(R734C) KI mice were viable with no apparent bleeding tendency. Platelet counts of heterozygous (Hetero), and homozygous (Homo) KI mice were decreased relative to those of wild-type (WT) mice [WT: 1095 ± 52 (x10 9/L), Hetero: 834 ± 93**, Homo: 445 ± 30** (mean±SD, **P<0.01 compared with WT, n=6 respectively)], with an increase in platelet size, indicating that β3(R734C) leads to macrothrombocytopenia. Moreover, the expression of αIIbβ3 and GPVI in platelets was decrease in KI mice like human subjects. Platelet aggregations were impaired in KI mice. JON/A binding was not detected on non-stimulated platelets and agonist-induced P-selectin and JON/A binding were impaired in homo KI mice, particularly in PAR4-AP stimulation. Platelet spreading on fibrinogen (Fgn) was impaired in KI mice with or without ADP and thrombin stimulation. Next, we analyzed megakaryocytes (Mgk) derived from bone marrow after 5 days incubation with murine thrombopoietin. Interestingly, the expression of αIIbβ3 in Mgk of KI mice was compatible with WT and the rate of filopodia and/or lamellipodia formation of Fgn-adhered Mgk was decreased in KI mice [WT: 78(%), Homo: 32(%) (P<0.01)]. RhoA activation was assessed by ELISA and it was significantly decreased in Fgn-adhered Mgk of KI mice [WT: 0.33±0.039, Homo: 0.16±0.029 (mean OD 490nm Δblank±SD, P<0.01)]. Finally, we observed impaired proplatelet formation of fetal liver derived-Mgk in KI mice [WT: 26.2±2.7(%), Homo: 15.2±1.9(%) (P<0.01)] with abnormal morphology (Figure 1). These results suggest that impaired αIIbβ3 outside-in signaling and cytoskeletal remodeling in KI mice lead to macrothrombocytopenia. Conclusions We revealed that a non-activating β3(R734C) is a causal mutation of macrothrombocytopenia in human and mouse. This mutation leads to impaired inside-out and outside-in signaling of αIIbβ3, which results in abnormal platelet production with impaired cytoskeletal reorganization. Our results also suggest that abnormal signaling induced by β3(R734C) causes reduced expression of GPVI, which has not been reported in other αIIbβ3-related macrothrombocytopenia.

In cis “benign” SOCS1 variants linked to enhanced interferon signaling and autoimmunity

We aimed to characterize the genetic basis of disease in a family with multiple autoimmune manifestations, including systemic lupus erythematosus (SLE), immune thrombocytopenia, and autoimmune thyroiditis. Whole exome sequencing (WES) was conducted to identify candidate variants, which were analyzed by flow cytometry, immunoblotting, immunoprecipitation, and luciferase reporter assay in transfected 293T cells. Gene expression in peripheral blood mononuclear cells (PBMC) was profiled by bulk RNA sequencing and plasma cytokines were measured by proximity extension assay.In two siblings with early-onset SLE and immune thrombocytopenia, WES identified two maternally inherited in cis variants (p. Pro50Leu and p.Ala76Gly) in Suppressor of cytokine signaling 1 (SOCS1), flanking the kinase inhibitory domain that interacts with Janus kinases (JAK). Both variants were predicted to be benign by most in silico algorithms and neither alone affected the ability of SOCS1 to inhibit JAK-STAT1 signaling by functional studies. When both variants were expressed in cis, the mutant SOCS1 protein displayed decreased binding to JAK1 and reduced capacity to inhibit type I interferon (IFN–I) signaling by ∼20–30% compared to the wildtype protein. PBMC from the probands and their mother showed increased expression of interferon-inducible genes compared to healthy controls, supporting defective regulation of IFN-I signaling. Cells from all three subjects displayed heightened sensitivity to IFN-I stimulation, while response to IFN-γ, IL-4, and IL-6 was comparable to healthy controls.Our work illustrates the critical fine-tuning of IFN-I signaling by SOCS1 to prevent autoimmunity. We show that a combination of genetic variants that are individually benign may have deleterious consequences.

Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor

Through a structure-based irreversible drug design approach, we have discovered a highly potent IDH1-mutant inhibitor compound 16 (IHMT-IDH1-053) (IC50 = 4.7 nM), which displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants. The crystal structure demonstrates that 16 binds to the IDH1 R132H protein in the allosteric pocket adjacent to the NAPDH binding pocket through a covalent bond with residue Cys269. 16 inhibits 2-hydroxyglutarate (2-HG) production in IDH1 R132H mutant transfected 293T cells (IC50 = 28 nM). In addition, it inhibits the proliferation of HT1080 cell line and primary AML cells which both bear IDH1 R132 mutants. In vivo, 16 inhibits 2-HG level in a HT1080 xenograft mouse model. Our study suggested that 16 would be a new pharmacological tool to study IDH1 mutant-related pathology and the covalent binding mode provided a novel approach for designing irreversible IDH1 inhibitors.

Palmitoylation regulates the magnitude of HCN4-mediated currents in mammalian cells.

The sinoatrial node (SAN) and subsidiary pacemakers in the cardiac conduction system generate spontaneous electrical activity which is indispensable for electrical and therefore contractile function of the heart. The hyperpolarisation-activated cyclic nucleotide-gated channel HCN4 is responsible for genesis of the pacemaker "funny" current during diastolic depolarisation. S-palmitoylation, the reversible conjugation of the fatty acid palmitate to protein cysteine sulfhydryls, regulates the activity of key cardiac Na+ and Ca2+ handling proteins, influencing their membrane microdomain localisation and function. We investigated HCN4 palmitoylation and its functional consequences in engineered human embryonic kidney 293T cells as well as endogenous HCN4 in neonatal rat ventricular myocytes. HCN4 was palmitoylated in all experimental systems investigated. We mapped the HCN4 palmitoylation sites to a pair of cysteines in the HCN4 intracellular amino terminus. A double cysteine-to-alanine mutation CC93A/179AA of full length HCN4 caused a ∼67% reduction in palmitoylation in comparison to wild type HCN4. We used whole-cell patch clamp to evaluate HCN4 current (IHCN4) in stably transfected 293T cells. Removal of the two N-terminal palmitoylation sites did not significantly alter half maximal activation voltage of IHCN4 or the activation slope factor. IHCN4 was significantly larger in cells expressing wild type compared to non-palmitoylated HCN4 across a range of voltages. Phylogenetic analysis revealed that although cysteine 93 is widely conserved across all classes of HCN4 vertebrate orthologs, conservation of cysteine 179 is restricted to placental mammals. Collectively, we provide evidence for functional regulation of HCN4 via palmitoylation of its amino terminus in vertebrates. We suggest that by recruiting the amino terminus to the bilayer, palmitoylation enhances the magnitude of HCN4-mediated currents, but does not significantly affect the kinetics.

Non-interfacial self-assembly of synthetic protocells

BackgroundProtocell refers to the basic unit of life and synthetic molecular assembly with cell structure and function. The protocells have great applications in the field of biomedical technology. Simulating the morphology and function of cells is the key to the preparation of protocells. However, some organic solvents used in the preparation process of protocells would damage the function of the bioactive substance. Perfluorocarbon, which has no toxic effect on bioactive substances, is an ideal solvent for protocell preparation. However, perfluorocarbon cannot be emulsified with water because of its inertia.MethodsSpheroids can be formed in nature even without emulsification, since liquid can reshape the morphology of the solid phase through the scouring action, even if there is no stable interface between the two phases. Inspired by the formation of natural spheroids such as pebbles, we developed non-interfacial self-assembly (NISA) of microdroplets as a step toward synthetic protocells, in which the inert perfluorocarbon was utilized to reshape the hydrogel through the scouring action.ResultsThe synthetic protocells were successfully obtained by using NISA-based protocell techniques, with the morphology very similar to native cells. Then we simulated the cell transcription process in the synthetic protocell and used the protocell as an mRNA carrier to transfect 293T cells. The results showed that protocells delivered mRNAs, and successfully expressed proteins in 293T cells. Further, we used the NISA method to fabricate an artificial cell by extracting and reassembling the membrane, proteins, and genomes of ovarian cancer cells. The results showed that the recombination of tumor cells was successfully achieved with similar morphology as tumor cells. In addition, the synthetic protocell prepared by the NISA method was used to reverse cancer chemoresistance by restoring cellular calcium homeostasis, which verified the application value of the synthetic protocell as a drug carrier.ConclusionThis synthetic protocell fabricated by the NISA method simulates the occurrence and development process of primitive life, which has great potential application value in mRNA vaccine, cancer immunotherapy, and drug delivery.Graphical

Molecular characteristics and the roles of CaASC and its restriction to Aeromonas hydrophila in Carassius auratus

Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), as a critical adaptor molecule in inflammasome complexes, plays an important role in mediating inflammation reaction. In this study, the complete cDNA of ASC gene with 891 bp was cloned in Qihe crucian carp Carassius auratus (named as CaASC), which was composed of a 5′-UTR of 36 bp, a 3′-UTR of 252 bp, and an ORF of 603 bp encoded 200 amino acids with a predicted isoelectric point of 5.61 and a molecular mass of 22.0 kDa. Multiple sequence alignment and motif analysis revealed that CaASC contained a conserved N-terminal Pyrin domain (PYD) and a C-terminal Caspase recruitment domain (CARD). CaASC mRNA and protein expressions were detected in selected tissues, with the highest mRNA level in the spleen. Meanwhile, CaASC gene expressions were clearly altered in intestine, gill, skin, spleen, liver and head kidney of fish challenged by Aeromonas hydrophila, LPS, and polyI:C, respectively. The recombined proteins of CaASC with fluorescent tag were over-expressed in transfected 293T cells, and the green specks were observed obviously and located in the cytoplasm. Furthermore, knockdown of CaASC reduced the expression of IL-1β and promoted the bacterial colonization in fish tissues, while overexpression of CaASC increased the expression of IL-1β and hampered the bacterial colonization in these tissues. Taken together, these results identified the molecular characteristics of CaASC in C. auratus, and revealed its role in regulating IL-1β expression and restricting bacterial infection in vivo.

In Vivo Crispr Screening Identifies Novel Vulnerabilities in ETO2/GLIS2-rearranged Leukemia

Background: CRISPR screening has allowed for massively parallel interrogation of the genome for vulnerabilities in a variety of cancer models. However, these experiments are largely performed in vitro due to the scale and conditions required to effectively conduct these screens. Furthermore, there still remain genetic subtypes of acute leukemia which are poorly represented among existing cell lines. We sought to determine the feasibility of conducting screens with focused libraries in patient-derived leukemia xenografts. Methods: We utilized a patient-derived acute megakaryoblastic leukemia (AMKL) bearing an ETO2/GLIS2 fusion, representing an aggressive subtype of pediatric acute leukemia with limited comparable cell lines (Gruber TA, et al. Cancer Cell 2012.) Based on its transplantability in NOD.scid.Il2Rγcnull-SGM3 (NSGS) mice vs culture in vitro, we performed all subsequent experiments in vivo. We first sought to establish stable Cas9 expression, which we successfully achieved by lentiviral transduction followed by FACS-enriched transplant, followed by a second round of FACS enrichment with limiting dilution transplant. As judged by mCherry flow cytometry, we achieved highly pure (>90%) Cas9-expressing populations, which we verified by western blotting. We further verified functionality of these cells by verifying cutting at the safe harbor locus AAVS1. In order to identify molecular vulnerabilities in this system, we identified the top 100 differentially expressed genes (DEG) between ETO2/GLIS2-rearranged leukemias versus other leukemia PDXs which we previously characterized. We included eight transcription factors with motifs enriched in our DEG analysis, as well as eight pan-essential positive controls (such as MYC, BRD4). Four guide RNAs (gRNA) per gene were selected from the Broad Brunello genome-wide library (Doench JG, et al. Nat Biotechnol 2016) as well as 50 "safe targeting" control guides (Morgens DW, et al. Nat Commun 2017) directed against non-essential genomic regions for a total of 518 guides. Guides were ordered as pooled oligonucleotides, cloned into a lentiviral gRNA backbone using standard techniques, then used to prepare lentivirus via transient transfection of 293T cells followed by titration to achieve an MOI of 0.3. With this MOI and an approximate engraftment frequency of 2% following intrafemoral injection, we transplanted 8.7e7 cells across eight NSGS mice to achieve adequate starting representation of our pooled library. Mice were sacrificed at humane endpoints, and spleens and bone marrow underwent PCR amplification for gRNA sequences followed by Illumina deep sequencing, and analysis with MAGeCK-VISPR (Wei L, et al. Genome Biol 2015). Results: One mouse per cohort was sacrificed at 24 hours post-transplant and sequenced for gRNA representation, which confirmed that library representation was largely preserved with our approach. At the time of sacrifice, spleen and bone marrow samples were independently sequenced, but no major bias in guide dropouts was observed between these compartments. Subsequent analyses were performed on the marrow alone. We observed the dropout of 38 genes with a false discovery rate < 0.25, including all positive control gRNAs as well as targets previously described to be essential through our own orthogonal experiments (BCL2) or previously published findings (GLIS2, GATA3) (Thirant C et al. Cancer Cell 2017). Among transcription factors found to be essential, we identified several which had not previously been strongly associated with acute leukemia (FOXD4L1, ZNF740). Conclusion: Patient-derived xenografts represent a unique platform for targeted functional genomic interrogation of acute leukemias. These screens can be performed with a tractable number of animals and modest sequencing requirements. Additional experiments are ongoing to identify the mechanistic implications of the vulnerabilities described here in ETO2/GLIS2-rearranged AMKL.

Establishment of High Titer Baboon Endogenous Retrovirus Envelope Pseudotyped Lentiviral Vector Production Protocol Focusing on Syncytium Formation and Exfoliation

Introduction Cytokine stimulation of hematopoietic stem cells (HSCs) for the expression of virus entry transporter is inevitable to obtain high transduction efficiency for VSVg envelope pseudotyped lentiviral vectors (VSVg-LVs). However, those stimulation induce apoptosis in HSCs derived from patients affected by DNA repair disorder, the establishment of novel transduction methods has been warranted. Sodium-dependent neutral amino acid transporter type-1 and type-2, which are the entry transporter for Baboon endogenous retrovirus (BaEV-Rless) envelope pseudotyped lentiviral vectors (BaEV-Rless-LVs), are highly expressed on the surface of HSCs in absence of cytokine stimulation. Therefore, BaEV-Rless-LVs could be an effective gene therapy tool to increase transduction in HSC with DNA repair-related mutations. However, production of high titer BaEV-Rless-LVs proved to be challenging compared to VSVg-LVs, as the titer of BaEV-Rless-LVs was one thousandth of VSVg-LVs. 293T cells transfected with helper plasmids, including BaEV-Rless plasmid, showed morphological changes such as syncytium formation and exfoliation, likely impairing cell viability and virus production. Therefore, for clinical applications, improved production of BaEV-Rless-LVs is mandatory. To this end, we modified the protocol to prevent the characteristic morphological changes, syncytium formation and exfoliation, which could be the causes of low virus titer. Methods In the attempt to increase viral production, we modified the VSVg-LVs "basic protocol" modified to produce BaEV-Rless-LVs: co-transfection of 0.44 µg of BaEV-Rless envelope plasmid, 1.464 µg of the self-inactivating HIV-1 derived vector encoding green fluorescent protein (GFP) under the control of spleen focus foamy virus promoter (SIN-HIV-SFFV-GFP), 0.336 μg of Rev regulatory plasmid and 0.74 μg of RRE plasmid to 293T cells per well of 6-well-plate, respectively. Virus titration was performed on 293T cells using serial dilution of the viral preparations and assessing 293T GFP+ cells using flow cytometry analysis. To investigate in detail the time-course of syncytium formation and exfoliation of transfected 293T cells, we used by time-lapse analysis to assess critical culture conditions and to guide us on how to further modify the protocol. Results Time-lapse analysis revealed that syncytium formation initiated at 8-hours post-transfection of the helper plasmids and terminated at 18-hours post-transfection. (Figure 1). Exfoliation started at 20-hours post-transfection, soon after completion of syncytium formation. As we hypothesized that the syncytium formation and exfoliation might be the cause of the low viral vector production, we modified three points of the basic protocol: the amount of BaEV-Rless plasmid, harvest timing of virus supernatant and use of poly-l-lysine (PLL) coated plate to avoid syncytium formation and exfoliation of 293T cells. First, to clarify whether the amount of BaEV-Rless plasmid was proportional to syncytium formation and virus titer, we changed the amounts of BaEV-Rless plasmid and compared titers. Interestingly, increasing 1.2-fold of the amount of plasmid raised the titer 3-fold despite syncytium formation. In contrast, even though smaller amounts of BaEV-Rless-plasmid did not induce syncytium formation and exfoliation, the titer of BaEV-Rless-LVs was reduced and/or undetectable. Next, we identified the optimal harvest time for viral titer. Harvest of viral supernatant at 48-hours post-transfection was associated with the highest titer despite completion of syncytium formation and exfoliation of 293T cells. Finally, we compared the titers with or without using PLL coated plate. Using PLL coated plate prevented exfoliation of transfected 293T cells and doubled the titer. Eventually, combination of using 1.2-folds of BaEV-Rless-plasmid, harvest of virus supernatant at 48-hours post-transfection and using PLL coated plate resulted in a 10-fold titer increase compared with the basic protocol (Figure 2). Conclusion Our novel high titer protocol for BaEV-Rless-LVs results in 10-fold titer increase compared to the basic protocol, and it could be utilized to develop clinical applications for DNA repair-related disorders. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Effect of Peroxiredoxin 6 on p53 Transcription Factor Level.

Peroxiredoxin 6 (Prdx6) is an important antioxidant enzyme with multiple functions in the cell. Prdx6 neutralizes a wide range of hydroperoxides, participates in phospholipid metabolism and cell membrane repair, and in transmission of intracellular and intercellular signals. Disruption of normal Prdx6 expression in the cell leads to the development of pathological conditions. Decrease in the Prdx6 concentration leads to increase in oxidative damage to the cell. At the same time, hyperproduction of Prdx6 is associated with increase in antioxidant status, suppression of apoptosis, and carcinogenesis. Currently, mechanisms of carcinogenic action of peroxiredoxins are poorly understood. In this work we established that the 3-4-fold increase in Prdx6 production in mouse embryonic fibroblast 3T3 cells leads to the 4-5-fold decrease in the level of oncosuppressor p53. At the same time, hyperproduction of Prdx6 leads to the increased expression of RELA and HIF1A, which have oncogenic effects. The 3-4-fold increase in intracellular Prdx6 increases intensity of cell proliferation by 20-30%, promotes increase in antioxidant activity by 30-50%, and increases radioresistance of the transfected 3T3 cells by 30-40%. Increase of the level of intranuclear Prdx6 leads to the decrease in expression of the DNA repair genes in response to radiation, indicating decrease in the genomic DNA damage. This work discusses possible molecular mechanisms of p53 suppression during Prdx6 hyperproduction, which could be used in the development of new approaches in cancer therapy.

STAT and Janus kinase targeting by human herpesvirus 8 interferon regulatory factor in the suppression of type-I interferon signaling

Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma (KS)-associated herpesvirus, is involved etiologically in AIDS-associated KS, primary effusion lymphoma (PEL), and multicentric Castleman’s disease, in which both viral latent and lytic functions are important. HHV-8 encodes four viral interferon regulatory factors (vIRFs) that are believed to contribute to viral latency (in PEL cells, at least) and/or to productive replication via suppression of cellular antiviral and stress signaling. Here, we identify vIRF-1 interactions with signal transducer and activator of transcription (STAT) factors 1 and 2, interferon (IFN)-stimulated gene factor 3 (ISGF3) cofactor IRF9, and associated signal transducing Janus kinases JAK1 and TYK2. In naturally infected PEL cells and in iSLK epithelial cells infected experimentally with genetically engineered HHV-8, vIRF-1 depletion or ablation, respectively, led to increased levels of active (phosphorylated) STAT1 and STAT2 in IFNβ-treated, and untreated, cells during lytic replication and to associated cellular-gene induction. In transfected 293T cells, used for mechanistic studies, suppression by vIRF-1 of IFNβ-induced phospho-STAT1 (pSTAT1) was found to be highly dependent on STAT2, indicating vIRF-1-mediated inhibition and/or dissociation of ISGF3-complexing, resulting in susceptibility of pSTAT1 to inactivating dephosphorylation. Indeed, coprecipitation experiments involving targeted precipitation of ISGF3 components identified suppression of mutual interactions by vIRF-1. In contrast, suppression of IFNβ-induced pSTAT2 was effected by regulation of STAT2 activation, likely via detected inhibition of TYK2 and its interactions with STAT2 and IFN type-I receptor (IFNAR). Our identified vIRF-1 interactions with IFN-signaling mediators STATs 1 and 2, co-interacting ISGF3 component IRF9, and STAT-activating TYK2 and the suppression of IFN signaling via ISGF3, TYK2-STAT2 and TYK2-IFNAR disruption and TYK2 inhibition represent novel mechanisms of vIRF function and HHV-8 evasion from host-cell defenses.

Abstract 3553: Harnessing soluble CD40L to enhance anti-tumor efficacy of Her2-LAMP DNA vaccine using UNITE࣪ platform

Abstract CD40 ligand (CD40L; CD154) is a transmembrane protein expressed on the surface of activated T cells, particularly on CD4 T cells, that stimulates CD40-dependent activation of antigen-presenting cells, resulting in enhancement of T cell and antibody responses. Soluble multimeric forms of CD40L (sCD40L) act as an effective adjuvant to enhance vaccine immunogenicity. We previously developed a Her2/Neu-LAMP DNA vaccine based on our proprietary UNITE࣪ (UNiversal Intracellular Targeted Expression) platform, which fuses a tumor-associated antigen with lysosomal associated membrane protein 1 (LAMP-1). To increase T cell responses induced by this vaccine, we developed a bicistronic DNA construct in which both the tumor antigen (Her2) fused with LAMP and sCD40L were expressed separately. Secretion of CD40L was confirmed by transient transfection of 293T cells with plasmid DNA followed by ELISA for sCD40L in the cell culture supernatant. Intradermal vaccination of mice with bicistronic Her2-LAMP-sCD40L elicited significantly enhanced Her2-specific T cell and antibody responses compared with mice immunized with Her2-LAMP DNA. Intracellular staining revealed that inclusion of sCD40L in the vaccine induced potent antigen specific T cell IFNγ production, primarily in CD4 T cells. Furthermore, in a murine TSA breast cancer model, Her2-LAMP-sCD40L significantly inhibited tumor growth and prolonged survival in a therapeutic vaccine setting, suggesting that this novel bicistronic vaccine is an effective strategy to promote anti-tumor efficacy in vivo. Ongoing studies are aimed at exploring vaccine-induced changes within the tumor microenvironment, including cytokine profiles, expression of PD-1/PD-L1, and effect on myeloid derived suppressor cells and NK cells. This new approach in bicistronic DNA vaccine design using the UNITE࣪ platform may provide future therapeutic benefit for multiple Her2-expressing cancer types. Citation Format: Wei Shen, Renhuan Xu, Yun-Ting Kao, Mohan Karkada, Teri Heiland. Harnessing soluble CD40L to enhance anti-tumor efficacy of Her2-LAMP DNA vaccine using UNITE࣪ platform [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3553.

TLR9 agonist suppresses choroidal neovascularization by restricting endothelial cell motility via ERK/c-Jun pathway.

Choroidal neovascularization (CNV) is the feature of neovascular age-related macular degeneration (AMD). It has been demonstrated that inflammation plays a key role in the development of CNV. Here we aim to investigate how TLR9 agonist (CpG-ODN), one of the key regulators of inflammatory responses, suppresses CNV in vivo. The cell viability was assessed by MTT and EdU test after CpG-ODN treatment. Endothelial cells gap assay, tube formation assay and transwell assay were practiced to observe how CpG-ODN affected the endothelial cells functions. The choroidal explants and laser-induced CNV model were built to investigate how CpG-ODN suppressed angiogenesis. The ERK and c-Jun expression were evaluated to assess if CpG-ODN affected cell proliferation. Flow cytometry and qPCR was practiced to observe how CpG-ODN regulated cell proliferation. Our data showed that CpG-ODN not only reduced CNV area in vivo, but also decreased the RPE damage. CpG-ODN inhibited endothelial cells from migration and forming tubes, while the effect was not toxic. EdU test and MTT test suggested that CpG-ODN inhibited endothelial cells proliferation. CpG-ODN significantly increased protein expression of phosphorylated c-Jun but reduced phosphorylated ERK in HUVECs, which was confirmed in ERK transfected 293T cells. JNK inhibitor abolished the suppression of endothelial cells migration and tube formation by CpG-ODN. The findings were also in agreement with the observation in CpG-ODN treated CNV eyes in vivo. The flow cytometry and qPCR data revealed that the suppression of cell motility by CpG-ODN was achieved by arresting endothelial cells cell cycle at G0/G1 phase. Our study demonstrated that CpG-ODN suppressed endothelial cell motility by restricting the cell cycle progression at G0/G1 phase, the effect of which was achieved by interacting with ERK/c-Jun pathways.

TNFα regulates the expression of the CSE gene in HUVEC.

The hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) signaling pathway is involved in several inflammatory conditions, where tumor necrosis factor-α (TNFα) is one of the inflammatory cytokines activated during sepsis. Therefore, the present study investigated the role of the NF-κB transcription factor binding site in the transcriptional regulation of the CSE gene in 293T cells following treatment with TNFα using luciferase assays, as well as using western blotting and reverse transcription-quantitative PCR to examine the effect of TNFα on CSE expression in HUVECs. After transfected 293T cells were incubated with various concentrations of TNFα for 1, 3, and 6 h, the wild-type promoter of the CSE gene increased significantly at 1 h compared to 0 h. By contrast, after the transfected 293T cells were incubated with various concentrations of TNFα for 1 h, the mutant-type promoter activity of the CSE gene decreased significantly compared to the wild-type. These results revealed that the DNA sequence GGGACATTCC on the CSE gene promoter was directly associated with the transcriptional regulation of the CSE gene in Human cells (293T cells) that's were treated with TNFα. This suggests that TNFα affects CSE gene expression, such that vascular endothelial cells respond to TNFα in the blood by regulating CSE expression. The regulatory mechanisms associated with the effects of TNFα on the transcriptional regulation of the CSE gene in HUVECs and the NF-κB pathway warrant further investigation.

Interaction with the CCT chaperonin complex limits APOBEC3A cytidine deaminase cytotoxicity.

The APOBEC3 cytidine deaminases are implicated as the cause of a prevalent somatic mutation pattern found in cancer genomes. The APOBEC3 enzymes act as viral restriction factors by mutating viral genomes. Mutation of the cellular genome is presumed to be an off-target activity of the enzymes, although the regulatory measures for APOBEC3 expression and activity remain undefined. It is therefore difficult to predict circumstances that enable APOBEC3 interaction with cellular DNA that leads to mutagenesis. The APOBEC3A (A3A) enzyme is the most potent deaminase of the family. Using proteomics, we evaluate protein interactors of A3A to identify potential regulators. We find that A3A interacts with the chaperonin-containing TCP-1 (CCT) complex, a cellular machine that assists in protein folding and function. Importantly, depletion of CCT results in A3A-induced DNA damage and cytotoxicity. Evaluation of cancer genomes demonstrates an enrichment of A3A mutational signatures in cancers with silencing mutations in CCT subunit genes. Together, these data suggest that the CCT complex interacts with A3A, and that disruption of CCT function results in increased A3A mutational activity.

DDRE-18. DEVELOPMENT OF EGFRvIII AND EGFR DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME

Abstract BACKGROUND Chimeric antigen receptor T cell (CART) therapy has revolutionized the treatment landscape for hematological malignancies, its efficacy remains limited in solid tumors. EGFRvIII is a truncated version of the wild type EGFR in which deletion of exons 2–7 of the extracellular domain leads the variant (EGFRvIII) that is strongly antigenic and is mostly expressed on tumor cells. EGFR amplification (tEGFR) almost uniformly precedes the presence of EGFRvIII on tumor cells. The heterogeneity of surface receptor expression and immunosuppressive stromal microenvironment underscore the need to develop CART strategies to target multiple tumor antigens simultaneously. METHODS we generated tEGFR/EGFRvIII directed CAR construct by cloning a clinically relevant tEGFR and EGFRvIII specific scFv into a second generation CAR construct (41BB stimulated) in a third generation lentivirus backbone. This was used to transfect 293T cells and the generated lentivirus particles were used to transduce T cells and generate EGFRvIII/tEGFR CART cells. GBM primary patient derived cell lines were used in these experiments. These cells were passaged and maintained in patient derived xenograft models. RESULTS EGFRvIII/tEGFR directed CART cells exhibited potent antitumor activity against EGFRvIII/tEGFR + GBM cell lines: with 100% killing at 1.25:1, 2.5:1, 5:1 and 10:1 E:T ratio on multiple PDX cell lines with EGFRvIII expression and EGFR over-expression (greater than five copies of EGFR gene) at 24 hours of incubation. Conclusion: We demonstrate that targeting EGFRvIII and over-expressed EGFR with CART cells is feasible, efficacious and represents a promising therapeutic strategy to target GMB. Data from in vivo and combinatorial CART experiments will be reported at the meeting.

Development of CAR-T Cell Constructs with Broad Anti-Tumor Tropism

Chimeric antigen receptor T (CAR-T) cell therapy is a transformative approach to cancer eradication. CAR-T is expensive in part due to the restricted use of each CAR construct for a specific set of tumors such as B cell lymphoma targeted with CD19 and multiple myeloma targeted with BCMA. A CAR construct with broad anti-tumor activity can be advantageous due to wide applicability and scalability of production. We show that CD126, the IL-6 receptor alpha, is an antigen that is expressed by many hematologic and solid malignancies including multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, pancreatic and prostate adenocarcinoma, non-small cell lung cancer and malignant melanoma amongst others. High CD126 expression is a negative prognostic marker in many malignancies. The two CD126 targeting CAR-T cell constructs contain the CD28 anchoring domain followed by 4-1BB and CD3 zeta signaling domain. Lentiviral vectors were generated with triple plasmid (CAR, psPAX2 and pMD2.G) transfection of 293T cells and the vector concentrated by ultracentrifugation and used to transduce human T cells. T cells were isolated from leuko-reduction cones using negative selection with magnetic beads. The transduction efficiency was around 60%. The T cells were activated with anti-CD3/CD28 beads and expanded for two weeks before using for downstream experiments. CD126 CAR-T cells are able to kill many tumor cells in an antigen specific manner and with an efficiency that is directly proportional to the cell surface expression of CD126 expression (rho = 0.6, p = 0.0019). The presence of soluble CD126 in the culture media did not interfere with CAR-T cell killing. The CAR-T constructs bind murine CD126. However, injection of CD126 targeting CAR-T cells in NSG mice did not lead to any evidence of hepatotoxicity and weight loss despite possible expression of this antigen on hepatocytes. In vivo studies in NSG mice with multiple myeloma (RPMI-8226) and prostate adenocarcinoma (DU-145) xenograft models (n=10 tumors per group) showed that the intravenously injected CD126 targeted CAR-T cells (107) infiltrated the tumors, expanded, produced human interferon gamma and killed the tumor cells (p&amp;lt;0.001). Bioluminescence imaging showed control of tumor growth in the actively treated tumors compared to the controls (p&amp;lt;0.05). At post mortem, mice injected with CD126 targeted CAR-T cells had smaller residual tumors compared to controls injected with non-engineered human T cells from the same donor. Binding of sIL-6R by CAR-T cells could mitigate cytokine release syndrome. In support of this, murine SAA-3 levels (the equivalent of human CRP) were lower in mice injected with CD126 CAR-T compared to controls (p&amp;lt;0.05), suggesting that binding of sIL-6R by CAR-T cells could mitigate cytokine release syndrome. CD126 provides a novel therapeutic for CAR-T cells in a broad variety of tumors with low risk of toxicity. Disclosures Dingli: Apellis: Consultancy; Millenium: Consultancy; Janssen: Consultancy; Bristol Myers Squibb: Research Funding; Sanofi-Genzyme: Consultancy; Alexion: Consultancy; Rigel: Consultancy; Karyopharm Therapeutics: Research Funding.

Nef homodimers down-regulate SERINC5 by AP-2–mediated endocytosis to promote HIV-1 infectivity

SERINC5 is a multipass intrinsic membrane protein that suppresses HIV-1 infectivity when incorporated into budding virions. The HIV-1 Nef virulence factor prevents viral incorporation of SERINC5 by triggering its down-regulation from the producer cell membrane through an AP-2-dependent endolysosomal pathway. However, the mechanistic basis for SERINC5 down-regulation by Nef remains elusive. Here we demonstrate that Nef homodimers are important for SERINC5 down-regulation, trafficking to late endosomes, and exclusion from newly synthesized viral particles. Based on previous X-ray crystal structures, we mutated three conserved residues in the Nef dimer interface (Leu112, Tyr115, and Phe121) and demonstrated attenuated homodimer formation in a cell-based fluorescence complementation assay. Point mutations at each position reduced the infectivity of HIV-1 produced from transfected 293T cells, the Jurkat TAg T-cell line, and donor mononuclear cells in a SERINC5-dependent manner. In SERINC5-transfected 293T cells, virion incorporation of SERINC5 was increased by dimerization-defective Nef mutants, whereas down-regulation of SERINC5 from the membrane of transfected Jurkat cells by these mutants was significantly reduced. Nef dimer interface mutants also failed to trigger internalization of SERINC5 and localization to Rab7+ late endosomes in T cells. Importantly, fluorescence complementation assays demonstrated that dimerization-defective Nef mutants retained interaction with both SERINC5 and AP-2. These results show that down-regulation of SERINC5 and subsequent enhancement of viral infectivity require Nef homodimers and support a mechanism by which the Nef dimer bridges SERINC5 to AP-2 for endocytosis. Pharmacological disruption of Nef homodimers may control HIV-1 infectivity and viral spread by enhancing virion incorporation of SERINC5.

Abstract B28: Cep55 regulates YAP/TAZ expression and localization during cell cycle progression

Abstract Cell cycle regulation plays a pivotal role in controlling cell proliferation and survival. Aberrant expression of cell cycle-associated genes generally afflicts cells with tumor-prone characteristics and promotes chromosome instability. Cep55 (Centrosome Protein 55kDa; also known as c10orf3 and FLJ10540) was identified as an important regulator of cytokinesis involved in cell growth and proliferation. It is associated with central spindle and midbody during cell cycle progression and cooperates with members of endosomal sorting complex required for transport (ESCRT) machinery to constrict intracellular bridge for cell abscission. In addition to cytokinesis, Cep55 is involved in regulating the PI3K/AKT pathway as well as promoting tumorigenesis. In search of novel Cep55 interplayers that may abrogate their expression upon loss of cep55 expression, we set out experiments with cultured cells exogenously expressed Flag-tagged wild type (wt) Cep 55 versus shRNAs against Cep55 and subjected immunoprecipitates to LC-MS/MS. The Hippo pathway components YAP and its paralogue TAZ were found to be diminished apparently in Cep55 null sample compared with wt counterpart. To confirm if Cep55 knockdown affects expression of Hippo pathway, we transfected 293T cells with Cep55 shRNAs and detected expression of Hippo core components with Western blots. Hippo components such as Merlin, Mst, and Lats are without effect in expression level, with the exception of YAP/TAZ whose expression was decreased extensively. Immunofluorescent microscopy reveals YAP/TAZ colocalized with Cep55 at central spindle and midbody during mitosis; however, depletion of Cep55 results in diffusion of YAP/TAZ at midbody, suggesting cep55 is required for midbody localization of YAP/TAZ. In contrast, knockdown of YAP/TAZ did not significantly alter Cep55 localization to the midbody ring but displays phenotype, such as multinuclear cells and micronuclei, similar to that observed in Cep55-depleted cells. Together our data provide evidence that Cep55-YAP/TAZ interaction plays an important role in cytokinesis and may support a biologic interplay between the Hippo-YAP and PI3K-AKT-mTOR pathways. Note: This abstract was not presented at the conference. Citation Format: Yen-Ming Lin, Chu-Han Wu, Pin Ouyang. Cep55 regulates YAP/TAZ expression and localization during cell cycle progression [abstract]. In: Proceedings of the AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; 2019 May 8-11; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(8_Suppl):Abstract nr B28.